Berenberg Bank restated their buy rating on shares of GSK (LON:GSK – Free Report) in a research report released on Tuesday morning,Digital Look reports. The firm currently has a GBX 2,200 target price on the stock.
A number of other analysts also recently issued reports on the company. Royal Bank Of Canada initiated coverage on GSK in a research note on Tuesday, September 8th. They issued a “sector perform” rating and a GBX 1,975 target price for the company. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research report on Tuesday, October 20th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a report on Thursday, October 29th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of GBX 2,064.38.
Read Our Latest Research Report on GSK
GSK Stock Up 0.1%
Shares of GSK stock opened at GBX 1,891 on Tuesday. The company has a current ratio of 0.86, a quick ratio of 0.73 and a debt-to-equity ratio of 126.38. The stock has a market cap of £75.77 billion, a P/E ratio of 16.05, a P/E/G ratio of 1.24 and a beta of 0.28. The stock has a 50 day moving average of GBX 1,841.86 and a 200 day moving average of GBX 1,949.08. GSK has a twelve month low of GBX 1,690 and a twelve month high of GBX 2,282.
GSK (LON:GSK – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported GBX 54.60 EPS for the quarter. The company had revenue of GBX 888.70 billion for the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. As a group, sell-side analysts expect that GSK will post 175.98 EPS for the current year.
Insider Buying and Selling
In other news, insider Jonathan Symonds acquired 1,500 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was acquired at an average cost of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal acquired 637 shares of the stock in a transaction on Friday, September 18th. The shares were acquired at an average cost of GBX 4,985 per share, for a total transaction of £31,754.45. In the last quarter, insiders acquired 2,151 shares of company stock valued at $6,021,921. 0.20% of the stock is owned by company insiders.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Recommended Stories
- Five stocks we like better than GSK
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
